Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

HRS9531

Aliases
HRS9531 injection, HRS9531 injection Placebo

11 clinical trials

5 indications

Indication
Type 2 Diabetes
Indication
Heart Failure with Preserved Ejection Fraction
Indication
Diabetes Mellitus
Indication
Type 2
Indication
Obesity
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Multi-center, Single-dose, Open-label, Parallel Design, Pharmacokinetics Study of HRS9531injection in Healthy Subjects and Subjects With Impaired Renal Function
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Relative Bioavailability Study of Single-dose, Randomized, Open-label, Single-period, Parallel Design of HRS9531 Injection Using Different Manufacturing Processes in Healthy Subjects
Status: Completed, Estimated PCD: 2023-09-04
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo- and Positive-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus
Status: Recruiting, Estimated PCD: 2023-03-29
Clinical trial
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administered HRS9531
Status: Completed, Estimated PCD: 2022-08-24
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes
Status: Active (not recruiting), Estimated PCD: 2024-10-08
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Overweight or Obese Subjects
Status: Not yet recruiting, Estimated PCD: 2024-08-01
Clinical trial
Efficacy and Safety of HRS9531 in Overweight or Obese Participants: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Status: Recruiting, Estimated PCD: 2025-07-30
Clinical trial
A Single-center, Double-blinded, Randomized, Placebo-controlled Trial to Evaluate the Effectiveness and Safety of Low-frequency Injection of HRS9531 in Control of Weight Regain in Obese Subjects With and Without Diabetes
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Phase I Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of HRS9531 Tablets in Healthy Subjects
Status: Not yet recruiting, Estimated PCD: 2024-09-30